Crizotinib, sold under the brand name Xalkori among others, is an anti-cancer medication used for the treatment of non-small cell lung carcinoma (NSCLC). It is particularly effective in patients whose cancer cells exhibit alterations in the ALK (anaplastic lymphoma kinase) or ROS1 genes. Crizotinib works by targeting and inhibiting these tyrosine kinase receptors, which are responsible for the growth and survival of cancer cells, thereby slowing or halting tumor progression.
Parent: Crizotinib
During the production and storage of Crizotinib, related compounds and impurities may form, which must be controlled to ensure the drug’s safety and efficacy. Regulatory authorities, such as the U.S. Food and Drug Administration (FDA), provide stringent guidelines on permissible impurity levels in Crizotinib formulations.
Key aspects of Crizotinib-related compounds and impurities include:
Advanced analytical methods, such as High-Performance Liquid Chromatography (HPLC), are employed to detect and quantify Crizotinib-related compounds and impurities, ensuring compliance with stringent quality standards.
Crizotinib is used to treat non-small cell lung carcinoma (NSCLC) in patients with alterations in the ALK or ROS1 genes. It helps to slow or stop the growth of cancer cells by targeting specific molecular pathways.
For patients with ALK-positive or ROS1-positive NSCLC, Crizotinib is often considered more effective than traditional chemotherapy due to its targeted approach, which minimizes damage to healthy cells and results in fewer side effects.
For patients with ALK-positive or ROS1-positive NSCLC, Crizotinib is often considered more effective than traditional chemotherapy due to its targeted approach, which minimizes damage to healthy cells and results in fewer side effects.
Crizotinib works by inhibiting the ALK and ROS1 tyrosine kinases, which are involved in cell growth and survival. By blocking these pathways, Crizotinib reduces tumor growth and prevents cancer cells from proliferating.
